Publications
Detailed Information
Clinical Factors Affecting the Effectiveness of 1550-nm Erbium-Doped Fractional Photothermolysis Laser for Individual Atrophic Acne Scar Types
Cited 0 time in
Web of Science
Cited 0 time in Scopus
- Authors
- Issue Date
- 2023-01-12
- Publisher
- Springer
- Citation
- Dermatology and Therapy, 13(1)
- Keywords
- 1550-nm erbium-doped fractional laser ; Atrophic acne scar ; Boxcar scar ; Rolling scar ; Icepick scar ; Isotretinoin ; Age
- Abstract
- Introduction
Although non-ablative fractional resurfacing is frequently used for atrophic acne scars, few studies have examined clinical factors affecting the effectiveness of non-ablative fractional laser in individual atrophic acne scar types (icepick, rolling, and boxcar scars). Herein, we evaluated the clinical factors affecting the effect of non-ablative fractional laser for individual atrophic acne scar types using objective assessment tools.
Methods
Thirty-one patients who had been treated by 1550-nm erbium-doped fractional laser for atrophic acne scars were retrospectively reviewed. Icepick, rolling, and boxcar scars were counted using photographs, and acne scar reduction efficiency (ASRE%; the percentage reduction of post-acne scar count from baseline counts) was calculated.
Results
The median count of each scar type was significantly reduced at the end of the final session. Boxcar scars responded better (median ASRE 59.2%) than rolling (ASRE 40.6%, p = 0.017) and icepick scars (ASRE 19.1%, p = 0.010). Concomitant isotretinoin use resulted in a greater ASRE and a significantly greater improvement in icepick scars. Patients aged 25years or younger showed a higher ASRE, with a greater improvement in boxcar scars.
Conclusion
1550-nm fractional laser treatment for atrophic acne scars was more effective in patients who were younger and taking isotretinoin concurrently.
- ISSN
- 2190-9172
2190-9172
- Language
- English
- Files in This Item:
- Appears in Collections:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.